Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)

Amylyx Pharmaceuticals (AMLX) has 3 years of Gross Margin data on record, last reported at 100.0% in Q4 2024.

  • For Q4 2024, Gross Margin rose 863.0% year-over-year to 100.0%; the TTM value through Sep 2025 reached 100.0%, up 771.0%, while the annual FY2024 figure was 93.19%, 13.0% down from the prior year.
  • Gross Margin reached 100.0% in Q4 2024 per AMLX's latest filing, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q3 2024 and bottomed at 68.56% in Q3 2022.
  • Average Gross Margin over 3 years is 92.18%, with a median of 93.96% recorded in 2023.
  • Peak YoY movement for Gross Margin: soared 2562bps in 2023, then tumbled -46bps in 2024.
  • A 3-year view of Gross Margin shows it stood at 87.11% in 2022, then increased by 5bps to 91.37% in 2023, then rose by 9bps to 100.0% in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 100.0% in Q4 2024, 100.0% in Q3 2024, and 99.22% in Q2 2024.